Tag: Non opioid analgesic

Following its FDA approval in early 2025, the manufacturer, Vertex Pharmaceuticals, established a wholesale acquisition cost (WAC) of $15.50 per 50mg pill for Journavx. For many patients, the final out-of-pocket cost will depend heavily on insurance coverage and available patient assistance options, making the question, **how much does Journavx cost in the US?**, more complex than the sticker price suggests.

Each year, acetaminophen is an ingredient in medications used for over 1 billion colds and flus in the U.S. [1.7.5]. A frequent question is, 'Is acetaminophen 325 mg tablet a narcotic?' The answer is definitively no; it is a non-opioid pain reliever and fever reducer [1.2.3, 1.9.1].

With over 8.5 million administrations globally, the 'green whistle,' or Penthrox, has been used for emergency pain relief in some countries since 1975. The central question for many remains: **is the green whistle safe** for its intended use in acute pain management?

According to a 2024 study, 90% of patients reported an overall good-to-excellent experience with Penthrox for pain relief, highlighting its favorable tolerability. However, a comprehensive understanding of its safety is crucial for healthcare providers and patients alike, making the question **How safe is Penthrox?** a vital one.

First synthesized in 1920, metamizole, also known as dipyrone, is a potent non-opioid analgesic with antipyretic and spasmolytic properties. Debates surrounding its complex mechanism of action often lead to the central question: is metamizole an opioid?

In 2023, approximately 24.3% of U.S. adults experienced chronic pain, with 8.5% suffering from high-impact chronic pain that limited their daily activities [1.8.2]. This widespread need drives the ongoing search to answer the question: what is the new narcotic pain pill offering effective and safer relief?

With more than 80,000 Americans dying annually from drug overdoses, most involving opioids, the need for safer, non-addictive pain management alternatives is urgent. This experimental compound, known as **SBI 810**, represents a significant step forward, offering effective relief in preclinical studies without the dangerous side effects associated with traditional opioid medications.